Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 210

1.

Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers.

Sadorge C, Ndiaye A, Beveridge N, Frazer S, Giemza R, Jolly N, Johnson J, Liddy H, Cosgrove CA, Allavena P, Mantovani A, Béchet S, Fontaine-Thompson A, Griffin GE, Dupont F, Sansonetti PJ, Lewis DJ.

Vaccine. 2008 Feb 13;26(7):978-87. doi: 10.1016/j.vaccine.2007.11.024. Epub 2007 Dec 3.

PMID:
18207287
[PubMed - indexed for MEDLINE]
2.

Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.

Launay O, Sadorge C, Jolly N, Poirier B, Béchet S, van der Vliet D, Seffer V, Fenner N, Dowling K, Giemza R, Johnson J, Ndiaye A, Vray M, Sansonetti P, Morand P, Poyart C, Lewis D, Gougeon ML.

Vaccine. 2009 Feb 18;27(8):1184-91. doi: 10.1016/j.vaccine.2008.12.021. Epub 2009 Jan 9.

PMID:
19135496
[PubMed - indexed for MEDLINE]
3.

Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.

McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, Bloom A, Taylor DN, Hale TL, Bourgeois AL.

Vaccine. 2008 Jun 19;26(26):3291-6. doi: 10.1016/j.vaccine.2008.03.079. Epub 2008 Apr 16.

PMID:
18468742
[PubMed - indexed for MEDLINE]
4.

Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.

Orr N, Katz DE, Atsmon J, Radu P, Yavzori M, Halperin T, Sela T, Kayouf R, Klein Z, Ambar R, Cohen D, Wolf MK, Venkatesan MM, Hale TL.

Infect Immun. 2005 Dec;73(12):8027-32.

PMID:
16299296
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.

Ranallo RT, Thakkar S, Chen Q, Venkatesan MM.

Vaccine. 2007 Mar 8;25(12):2269-78. Epub 2006 Dec 20.

PMID:
17229494
[PubMed - indexed for MEDLINE]
6.

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, Hartman AB, Venkatesan MM, Taylor DN, Hale TL.

Infect Immun. 2004 Feb;72(2):923-30.

PMID:
14742537
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.

Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, Sztein MB, Picking WD, Levine MM.

J Infect Dis. 2004 Nov 15;190(10):1745-54. Epub 2004 Oct 19. Erratum in: J Infect Dis. 2005 Jun 15;191(12):2161.

PMID:
15499528
[PubMed - indexed for MEDLINE]
Free Article
8.

Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.

Rahman KM, Arifeen SE, Zaman K, Rahman M, Raqib R, Yunus M, Begum N, Islam MS, Sohel BM, Rahman M, Venkatesan M, Hale TL, Isenbarger DW, Sansonetti PJ, Black RE, Baqui AH.

Vaccine. 2011 Feb 1;29(6):1347-54. doi: 10.1016/j.vaccine.2010.10.035. Epub 2010 Oct 30.

PMID:
21040694
[PubMed - indexed for MEDLINE]
9.

Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain.

Samandari T, Kotloff KL, Losonsky GA, Picking WD, Sansonetti PJ, Levine MM, Sztein MB.

J Immunol. 2000 Feb 15;164(4):2221-32.

PMID:
10657678
[PubMed - indexed for MEDLINE]
Free Article
10.

Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine.

Venkatesan MM, Hartman AB, Newland JW, Ivanova VS, Hale TL, McDonough M, Butterton J.

Infect Immun. 2002 Jun;70(6):2950-8.

PMID:
12010984
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit.

Wu T, Grassel C, Levine MM, Barry EM.

Infect Immun. 2011 Dec;79(12):4912-22. doi: 10.1128/IAI.05814-11. Epub 2011 Oct 3.

PMID:
21969003
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults.

Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL.

Infect Immun. 2002 Apr;70(4):2016-21.

PMID:
11895966
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.

McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, Forbes E, Tian JH, Yang HH, Pace JL, Jackson WJ, Bourgeois AL.

Vaccine. 2006 May 1;24(18):3735-45. Epub 2005 Jul 21.

PMID:
16095766
[PubMed - indexed for MEDLINE]
14.

Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.

Kotloff KL, Noriega F, Losonsky GA, Sztein MB, Wasserman SS, Nataro JP, Levine MM.

Infect Immun. 1996 Nov;64(11):4542-8.

PMID:
8890204
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.

Barnoy S, Baqar S, Kaminski RW, Collins T, Nemelka K, Hale TL, Ranallo RT, Venkatesan MM.

Vaccine. 2011 Aug 26;29(37):6371-8. doi: 10.1016/j.vaccine.2011.04.115. Epub 2011 May 17.

PMID:
21596086
[PubMed - indexed for MEDLINE]
16.

Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.

Turner AK, Beavis JC, Stephens JC, Greenwood J, Gewert C, Thomas N, Deary A, Casula G, Daley A, Kelly P, Randall R, Darsley MJ.

Infect Immun. 2006 Feb;74(2):1062-71.

PMID:
16428753
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Live-attenuated Shigella vaccines.

Venkatesan MM, Ranallo RT.

Expert Rev Vaccines. 2006 Oct;5(5):669-86. Review.

PMID:
17181440
[PubMed - indexed for MEDLINE]
18.

Recombinant Shiga toxin B subunit elicits protection against Shiga toxin via mixed Th type immune response in mice.

Gupta P, Singh MK, Singh Y, Gautam V, Kumar S, Kumar O, Dhaked RK.

Vaccine. 2011 Oct 19;29(45):8094-100. doi: 10.1016/j.vaccine.2011.08.040. Epub 2011 Aug 19.

PMID:
21856355
[PubMed - indexed for MEDLINE]
19.

Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery.

Levine MM, McEwen J, Losonsky G, Reymann M, Harari I, Brown JE, Taylor DN, Donohue-Rolfe A, Cohen D, Bennish M, et al.

J Clin Microbiol. 1992 Jul;30(7):1636-41.

PMID:
1629317
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers.

Li A, Kärnell A, Huan PT, Cam PD, Minh NB, Trâm LN, Quy NP, Trach DD, Karlsson K, Lindberg G, et al.

Vaccine. 1993;11(2):180-9.

PMID:
8438616
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk